Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Assets for 10 consecutive years, with $24.2 million as the latest value for Q4 2025.

  • Quarterly Assets fell 61.15% to $24.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.2 million through Dec 2025, down 61.15% year-over-year, with the annual reading at $24.2 million for FY2025, 61.15% down from the prior year.
  • Assets for Q4 2025 was $24.2 million at Rein Therapeutics, down from $53.7 million in the prior quarter.
  • The five-year high for Assets was $109.4 million in Q2 2024, with the low at $12.8 million in Q3 2023.
  • Average Assets over 5 years is $53.5 million, with a median of $54.2 million recorded in 2021.
  • The sharpest move saw Assets soared 712.8% in 2024, then plummeted 61.15% in 2025.
  • Over 5 years, Assets stood at $48.5 million in 2021, then plummeted by 54.61% to $22.0 million in 2022, then skyrocketed by 381.7% to $106.0 million in 2023, then crashed by 41.33% to $62.2 million in 2024, then tumbled by 61.15% to $24.2 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $24.2 million, $53.7 million, and $57.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.